Carregant...
Effect of Ivacaftor on Objective and Subjective Measures of Cough in Patients with Cystic Fibrosis
BACKGROUND AND OBJECTIVES: Cough is a major symptom in cystic fibrosis. Ivacaftor is a novel drug which targets the G551D mutation and has been demonstrated to improve lung function and weight in the long term. It also improves symptoms of extra-oesophageal reflux. We wanted to evaluate the effect o...
Guardat en:
| Publicat a: | Open Respir Med J |
|---|---|
| Autors principals: | , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Bentham Open
2016
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5299558/ https://ncbi.nlm.nih.gov/pubmed/28217196 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2174/1874306401610010105 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|